Boston Scientific (BSX) Could Be 31% Undervalued Following Its Three Segment Reorganization

Boston Scientific (BSX) put fresh focus on its structure after naming Joseph M. Fitzgerald as chief operating officer, along with a new three-segment model covering Interventional Therapies, Rhythm Solutions and MedSurg.

For investors, the timing is tricky. Boston Scientific’s recent reorganization news lands after a share price that is now US$42.04 and has fallen about 6% over the past month and quarter, with total shareholder return down sharply over the past year and more moderate declines over three and five years. This points to fading momentum as the market reassesses both growth potential and risk.

Compare Boston Scientific’s restructuring story with other potential healthcare opportunities by scanning our hand picked 32 healthcare AI stocks that could be setting up for their next major move.

Boston Scientific looks like a solid medical device franchise on paper, yet the share price slide and current US$42.04 tag tell a different story. Is this business-quality mismatch giving you a fair entry or just fair value?

Most Popular Narrative: 31.2% Undervalued

Against Boston Scientific’s last close of $42.04, the most followed narrative pins fair value at $61.07 using a 7.86% discount rate. That gap puts the focus squarely on whether future cost savings and new product platforms can outweigh today’s softer demand in key product lines.

The main factor that has to go right is that interventional cardiology and vascular therapies continue to grow solidly and that acquisitions like Penumbra and the MiRus TAVR option integrate effectively enough to offset weaker EP and LAAC demand and the impact of the cyberattack.

See why 82 investors see Boston Scientific as 31% undervalued.

Result: Fair Value of $61.07 (UNDERVALUED)

Still, the Boston Scientific story can crack if WATCHMAN and Electrophysiology remain weak for a longer period, or if the planned Penumbra and MiRus deals prove harder to integrate.

Find out about the key risks to this Boston Scientific narrative.

Next Steps

Mixed sentiment around Boston Scientific is clear, so move quickly, test the assumptions against your own thresholds, and weigh 4 key rewards and 1 important warning sign.

Looking for more Boston Scientific style ideas?

Boston Scientific may be front of mind today, but your next strong candidate could already be hiding in plain sight on a focused screener.

• Target resilient balance sheets before capital dries up by scanning our list of solid balance sheet and fundamentals (25 results), built to spotlight fundamentals that hold up under pressure.
• Hunt for quality selling at a discount by reviewing the 27 high quality undervalued stocks, curated to highlight companies with strong cash generation and supportive valuations.
• Stack potential income alongside capital growth by checking the 8 dividend fortresses, which focuses on higher yielding businesses with room to sustain payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com